MX2022012001A - Tratamiento preventivo de la migra?a. - Google Patents

Tratamiento preventivo de la migra?a.

Info

Publication number
MX2022012001A
MX2022012001A MX2022012001A MX2022012001A MX2022012001A MX 2022012001 A MX2022012001 A MX 2022012001A MX 2022012001 A MX2022012001 A MX 2022012001A MX 2022012001 A MX2022012001 A MX 2022012001A MX 2022012001 A MX2022012001 A MX 2022012001A
Authority
MX
Mexico
Prior art keywords
migraine
preventative treatment
rimegepant
disclosed
pharmaceutical compositions
Prior art date
Application number
MX2022012001A
Other languages
English (en)
Inventor
Vladimir Coric
Robert Croop
Original Assignee
Biohaven Pharmaceutical Ireland Dac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Ireland Dac filed Critical Biohaven Pharmaceutical Ireland Dac
Publication of MX2022012001A publication Critical patent/MX2022012001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan métodos para el tratamiento preventivo de la migraña, al administrar a un paciente que lo necesite rimegepant o una sal aceptable desde el punto de vista farmacéutico de este. Además, se divulgan composiciones farmacéuticas que comprenden rimegepant y kits que incluyen las composiciones farmacéuticas e instrucciones.
MX2022012001A 2020-03-29 2021-03-29 Tratamiento preventivo de la migra?a. MX2022012001A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063001341P 2020-03-29 2020-03-29
US202063111138P 2020-11-09 2020-11-09
US202063125247P 2020-12-14 2020-12-14
PCT/US2021/024551 WO2021202321A1 (en) 2020-03-29 2021-03-29 Preventative treatment of migraine

Publications (1)

Publication Number Publication Date
MX2022012001A true MX2022012001A (es) 2022-10-21

Family

ID=77929752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012001A MX2022012001A (es) 2020-03-29 2021-03-29 Tratamiento preventivo de la migra?a.

Country Status (11)

Country Link
US (1) US20230321066A1 (es)
EP (1) EP4125899A4 (es)
JP (1) JP2023533634A (es)
KR (1) KR20230015324A (es)
CN (1) CN115697335A (es)
AU (1) AU2021247101A1 (es)
BR (1) BR112022019338A2 (es)
CA (1) CA3176432A1 (es)
IL (1) IL296872A (es)
MX (1) MX2022012001A (es)
WO (1) WO2021202321A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117425728A (zh) * 2022-03-10 2024-01-19 宁波酶赛生物工程有限公司 用于合成乌布吉泮中间体的生物催化剂和方法
CN118717761A (zh) * 2024-05-27 2024-10-01 复旦大学 瑞美吉泮在制备治疗/预防阿尔茨海默病药物中的应用
CN120733002B (zh) * 2025-09-03 2025-11-25 华中科技大学同济医学院附属同济医院 Cgrp受体小分子拮抗剂在制备治疗嗜酸性慢性鼻窦炎伴鼻息肉的药品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3053158A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
PT4088720T (pt) * 2018-03-25 2025-10-15 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant para distúrbios relacionados com o cgrp
EP3817766A2 (en) * 2018-07-05 2021-05-12 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives
IL295926A (en) * 2020-02-27 2022-10-01 Biohaven Pharmaceutical Holding Company Ltd Virgin Island Brited Company ׂLtdׁD Brr Fast-dispersing oral dosage form of Rimgefent

Also Published As

Publication number Publication date
JP2023533634A (ja) 2023-08-04
IL296872A (en) 2022-11-01
US20230321066A1 (en) 2023-10-12
KR20230015324A (ko) 2023-01-31
WO2021202321A1 (en) 2021-10-07
CA3176432A1 (en) 2021-10-07
CN115697335A (zh) 2023-02-03
EP4125899A4 (en) 2024-06-12
EP4125899A1 (en) 2023-02-08
BR112022019338A2 (pt) 2022-12-06
AU2021247101A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021002321A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
ZA202403388B (en) Small molecules for treatement of cancer
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2022003845A (es) Tratamientos cognitivos medicinales.
WO2021022058A3 (en) Antiarrhythmic formulation
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
PH12022553376A1 (en) Acalabrutinib maleate dosage forms
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202193276A1 (ru) Способы лечения холангиокарциномы
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.